

## Curriculum Vitae

### Personal information Esther Werner

#### Work experience

---

1. Employer: National Veterinary Institute for Pharmaceuticals and Immunologicals, Berlin
  - Start date: 091986
  - End date: 121990
  - Position: Scientist and assessor in veterinary immunological department
  - Activities: \_ Scientific assessment of new applications, variations and renewals of immunological veterinary medicinal products \_ Batch testing of virus vaccines and diagnostics \_ Clinical research in development of immunologicals
  - Country: Germany
2. Employer: Paul\_Ehrlich\_Institut (Federal Institute for Vaccines and Biomedicines), Langen,
  - Start date: 011991
  - End date:
  - Position: Acting Head of Vet Division (since 10/2018); Head of section Assessment of IVMPS
  - Activities: Regulatory and scientific work in pre\_marketing assessment (assessor for new applications) and post marketing surveillance (variations, renewals, pharmacovigilance) of immunological veterinary medicinal products \_ Assessment of quality, safety and efficacy of IVMPS \_ Involved in CVMP scientific advices and in centralised, MRP, DCP and national marketing authorisation procedures \_ Assessment of monoclonal antibodies, cell based products and other biotechnological products \_ Batch testing of vaccines, immun sera and tuberculins \_ Adverse reaction and PSUR assessment \_ Research projects on alternatives to animal testing in vaccine quality control, development of methods to replace/refine animal experiments and validation of batch potency tests
  - Country: Germany

#### Education and training

---

1. Subject: Humboldt\_University of Berlin
  - Start date: 091981
  - End date: 071986
  - Qualification: Diploma of Veterinary Medicine
  - Organisation: studies of veterinary medicines
  - Country: Germany
2. Subject: Humboldt\_University of Berlin
  - Start date: 121987
  - End date: 121991
  - Qualification: Doctor of Veterinary Medicine (Dr. med. vet.)
  - Organisation: Veterinary Medicine – veterinary virology and microbiology
  - Country: Germany

#### Additional information

---

##### Publications

Jungbaeck C, Werner E, von Messling V. Regulatory aspects of the development, licensing, and availability of immunological veterinary products. berl. münch. tierärztl. wschr. 128 (2015), 473\_477. Roos K, Werner E, Lössner H. Multicopy integration of mini\_Tn7 transposons into selected chromosomal sites of a *Salmonella* vaccine strain. Vol. 8, Issue 1. Jan 2015. 177–187. Balks E, Gyra H, Kobe B, Cussler K, Werner E. Development and validation of a serological potency test for the release of *Leptospira* vaccines \_ Requirements in the European Union. Biologicals. 2013 Sep;41(5):325\_9. doi:10.1016/j.biologicals.2013.06.011. Epub 2013 Aug 1. Balks E, Wolf C, Loessner H, Werner E. Towards in vitro potency testing of inactivated erysipelas vaccines. Dev Biol (Basel). 2012;134:37\_44. Rosskopf, U., Noeske, K., Werner, E. (2005) Efficacy demonstration of tetanus vaccines by double antigen ELISA. Pharmeuropa Bio 2005.1, S. 31\_51 Rosskopf, U., Noeske, K., Werner, E. (2005) Replacement of the *in vivo* neutralisation test for efficacy demonstration of tetanus vaccines ad us. vet. ALTEX 2005/3, S. 169\_174 Rosskopf\_Streicher, U., Volkers, P., Noeske, K., Werner, E. (2004) Quality Assurance of *C. perfringens* Epsilon Toxoid Vaccines \_ ELISA Versus Mouse Neutralisation Test. ALTEX, Suppl. Linz 03/2004: 65\_69 Esther Werner Vaccines for Minor Species and Minor Indications \_ Current Situation and Concepts in Germany as well as Feasible Approaches for the Future \_ Authorities' View \_ Proceedings, International Veterinary Meeting on Consideration of Alternative Licensing Procedures for Vaccines for Minor Species, Minor Indications and Autogenous/Autologous Products, 29. – 31. Oktober 2003, Langen Rosskopf\_Streicher, U., Volkers, P., Werner, E. (2003) Control of Clostridium perfringens Vaccines using an Indirect Competitive ELISA for the Epsilon Toxin Component. Pharmeuropa Bio 2003\_2: 91\_96 A. Hoffmann, E. Werner, A. Mergel und K. Cußler (2003) Unerwünschte Wirkungen nach Applikation immunologischer Arzneimittel beim Tier. Deutsches Tierärzteblatt. 12: 1246\_1251 Cußler, K., Borrmann, E. und Werner, E. (2002) Fortschritte beim Ersatz von Tiersuchen in der Qualitätskontrolle von Clostridien\_Impfstoffen. Dtsch. Tierärztl. Wschr. 109: 172\_173 Luick, K., Gottschaldt, J., Schulze, F., Werner, E., Erler, W., Borrmann, E., (2002) Anwendung des Toxin\_Bindungs\_Inhibitionstests zur Wirksamkeitsprüfung von Clostridium -novyi\_Typ\_B\_Alphatoxoid\_Impfstoffen. Dtsch. Tierärztl. Wschr. 109: Ebert, E.; Öppling, V.; Werner, E.; Cussler, K. (1999) Development and prevalidation of two different ELISA systems for the potency testing of Clostridium perfringens  $\beta$ \_ and  $\epsilon$ \_toxoid containing veterinary vaccines. FEMS Immunology and Medical Microbiology 24: 299\_311 Ebert, E.; Öppling, V.; Werner, E.; Cussler, K.; (1999) Ersatz von Tiersuchen bei der Wirksamkeitsprüfung von veterinärmedizinischen Clostridien\_Immunpräparaten. Tierärztliche Umschau 54: 28\_33 Elvira Ebert, Volker Öppling, Esther Werner und Klaus Cußler Optimierung und Etablierung von serologischen Methoden für die Wirksamkeitsprüfung von Immunglobulinen gegen *Clostridium tetani*\_Toxin Optimisation and establishing of serological methods for the potency testing of immunglobulins against *Clostridium tetani*\_toxin (Altex Archiv Suppl. 1/98) Elvira Ebert, Entwicklung und Prävalidierung von Alternativmethoden zur Wirksamkeitsprüfung

von Clostridium perfringens\_Impfstoffen [http://www.zet.or.at/ALTEX/issues/1998/supp/S\\_98ebert1.htm](http://www.zet.or.at/ALTEX/issues/1998/supp/S_98ebert1.htm) Elvira Ebert, Manuela Kusch, Volker Öppling, Esther Werner und Klaus Cussler Serologische Wirksamkeitsprüfung von Clostridium perfringens\_betatoxoidhaltigen Veterinärimpfstoffen \_ eine Alternative zum gesetzlich vorgeschriebenen Mäuseneutralisationstest (Altex Archiv Suppl. 2/96)

**Projects**  
Research projects on alternatives to animal testing in vaccine quality control, development of methods to replace/refine animal experiments and validation of batch potency tests

**Memberships**  
DE CVMP Member or alternate since 12/2011 Chair of CVMP IWP since 12/2013 Member VICH BQM\_EWG Member ADVENT group (until 2020) Member OEG Bacteriophages Member of the BSP\_SC at EDQM Member CVMP SAWPV DE Alternate CVMP 12/2011 to 01/2020 Chair of CMDv 11/2005 to 09/2014 European Working groups (e.g. CMDv/VMRFG, CTS subgroup, CTS usergroup, Pharmacovigilance WP vet, Variation TF, ESS group)

#### Other Relevant Information